Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-partnered I/O drug

The checkpoint frenzy in the immuno-oncology sphere has largely focused on blocking the ligand-receptor duo of PD-L1 and PD-1, which cancer cells use to shield themselves from the immune system.